Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/P53 Mutant Lung Cancer

Cancers - Switzerland
doi 10.3390/cancers11040462
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast Care
SurgeryOncology
2016English

P1.01-69 Validation of the Lung Immune Prognostic Index (LIPI): Useful to Identify Resistance to PD-1 Checkpoint Inhibitors in Pretreated Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

TNFα Blockade Overcomes Resistance to Anti-Pd-1 in Experimental Melanoma

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2017English

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Ex on 14 Mutant Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2018English

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer

Frontiers in Oncology
Cancer ResearchOncology
2020English

Pd-1 Immune Checkpoint Blockade Improves Anti-Cd20 Based Immunotherapy in Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients With Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Checkpoint Blockade Therapy Resistance in Hodgkin's Lymphoma

The Lancet
Medicine
2018English

A Novel Mutant P53 Binding Partner BAG5 Stabilizes Mutant P53 and Promotes Mutant P53 GOFs in Tumorigenesis

Cell Discovery
BiochemistryGeneticsCell BiologyMolecular Biology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy